Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.

Adamas recently reported their Q1 earnings report with a slight beat on EPS and slight miss on revenue.

Adamas Pharmaceuticals: Was It Overrated?

Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adamas (ADMS) Upgraded to Buy: Here's Why

Adamas Pharmaceuticals, Inc. (ADMS) CEO Gregory Went on Q1 2019 Results - Earnings Call Transcript

Adamas (ADMS) delivered earnings and revenue surprises of 4.42% and -8.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Lags Revenue Estimates

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Adamas Pharmaceuticals (ADMS) Report Negative Q1 Earnings? What You Should Know

The company beat expectations on EPS and revenues, but the share price plummeted after a disappointing earnings conference call.

News for Adamas Pharmaceuticals Stock (ADMS)